Cargando…

Adjunctive Brexpiprazole and Functioning in Major Depressive Disorder: A Pooled Analysis of Six Randomized Studies Using the Sheehan Disability Scale

BACKGROUND: Patients with major depressive disorder and inadequate response to antidepressant treatments may experience a prolonged loss of functioning. This post hoc analysis aimed to determine the effect of adjunctive brexpiprazole on functioning in such patients. METHODS: A pooled analysis of dat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hobart, Mary, Zhang, Peter, Weiss, Catherine, Meehan, Stine Rasmussen, Eriksson, Hans
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Regular Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6403084/ https://www.ncbi.nlm.nih.gov/pubmed/30508090 http://dx.doi.org/10.1093/ijnp/pyy095

Ejemplares similares

Effects of Brexpiprazole Across Symptom Domains in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies
por: Marder, Stephen R, et al.
Publicado: (2021)

Adjunctive brexpiprazole for elderly patients with major depressive disorder: An open‐label, long‐term safety and tolerability study
por: Lepola, Ulla, et al.
Publicado: (2018)

Effect of Brexpiprazole on Prolactin: An Analysis of Short- and Long-Term Studies in Schizophrenia
por: Ivkovic, Jelena, et al.
Publicado: (2019)

A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder
por: Hobart, Mary, et al.
Publicado: (2019)

PS152. Efficacy and safety of brexpiprazole (OPC-34712) as adjunctive treatment in major depressive disorder: Meta-analysis of two pivotal studies
por: Eriksson, Hans, et al.
Publicado: (2016)

Effects of adjunctive brexpiprazole on calmness and life engagement in major depressive disorder: post hoc analysis of patient-reported outcomes from clinical trial exit interviews
por: Weiss, Catherine, et al.
Publicado: (2021)

A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia
por: Forbes, Andy, et al.
Publicado: (2018)

Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study
por: Davis, Lori L., et al.
Publicado: (2016)

Brexpiprazole as Adjunctive Treatment for Major Depressive Disorder Following Treatment Failure With at Least One Antidepressant in the Current Episode: a Systematic Review and Meta-Analysis
por: Kishi, Taro, et al.
Publicado: (2019)

Spotlight on brexpiprazole and its potential in the treatment of schizophrenia and as adjunctive therapy for the treatment of major depression
por: Bruijnzeel, Dawn, et al.
Publicado: (2016)

Reliability and validity of the Sheehan disability scale modified for pathological gambling
por: Hodgins, David C
Publicado: (2013)

The Translation and Psychometric Assessment of the Persian Version of the Sheehan Disability Scale
por: Amin-Esmaeili, Masoumeh, et al.
Publicado: (2014)

Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning
por: Fava, Maurizio, et al.
Publicado: (2016)

Efficacy of Brexpiprazole as Adjunctive Treatment in Major Depressive Disorder With Irritability: Post Hoc Analysis of 2 Pivotal Clinical Studies
por: Fava, Maurizio, et al.
Publicado: (2017)

Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies
por: Thase, Michael E, et al.
Publicado: (2018)

Effect of Brexpiprazole on Prolactin and Sexual Functioning: An Analysis of Short- and Long-Term Study Data in Major Depressive Disorder
por: Clayton, Anita H., et al.
Publicado: (2020)

Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study
por: Fleischhacker, W. Wolfgang, et al.
Publicado: (2016)

Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies
por: Weiller, Emmanuelle, et al.
Publicado: (2017)

O7.5. LONG-TERM SAFETY AND TOLERABILITY OF BREXPIPRAZOLE IN PATIENTS WITH SCHIZOPHRENIA
por: Hakala, Mika, et al.
Publicado: (2018)

Real-World Economic Outcomes of Brexpiprazole and Extended-Release Quetiapine Adjunctive Use in Major Depressive Disorder
por: Seetasith, Arpamas, et al.
Publicado: (2019)

M191. EFFECT OF BREXPIPRAZOLE ON ENGAGEMENT IN PATIENTS WITH SCHIZOPHRENIA: POST-HOC ANALYSIS OF THREE STUDIES
por: Ismail, Zahinoor, et al.
Publicado: (2020)

Disability during Early Pregnancy: Using the Sheehan Disability Scale during the First Trimester in Japan
por: Hada, Ayako, et al.
Publicado: (2022)

Psychometric evaluation of the Swedish Child Sheehan Disability Scale in adolescent psychiatric patients
por: Soler, Catalina Tores, et al.
Publicado: (2021)

Efficacy and safety of brexpiprazole in patients with schizophrenia presenting with severe symptoms: Post-hoc analysis of short- and long-term studies
por: Meade, Nicole, et al.
Publicado: (2020)

PS151. Adjunctive brexpiprazole (OPC-34712) in patients with major depressive disorder and anxiety symptoms: an exploratory study
por: Davis, Lori, et al.
Publicado: (2016)

Brexpiprazole for the Treatment of Agitation in Alzheimer Dementia: A Randomized Clinical Trial
por: Lee, Daniel, et al.
Publicado: (2023)

Psychometric evaluation of the Sheehan Disability Scale in adult patients with attention-deficit/hyperactivity disorder
por: Coles, Theresa, et al.
Publicado: (2014)

Sheehan’s Syndrome Presenting as Major Depressive Disorder
por: Qadri, Mehmood I, et al.
Publicado: (2015)

Evaluating functional disability in clinical trials of lisdexamfetamine dimesylate in binge eating disorder using the Sheehan Disability Scale
por: Yee, Karen S., et al.
Publicado: (2020)

Assessment of functional outcomes by Sheehan Disability Scale in patients with major depressive disorder treated with duloxetine versus selective serotonin reuptake inhibitors
por: Sheehan, David V., et al.
Publicado: (2016)

PS156. Adjunctive brexpiprazole, a novel effective strategy for treating Major depressive disorder?: Systematic review and Meta-analysis
por: Yoon, Seoyoung, et al.
Publicado: (2016)

The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies
por: Weiss, Catherine, et al.
Publicado: (2018)

PM421. Efficacy and safety of brexpiprazole (OPC-34712) in acute schizophrenia: a pooled analysis of two pivotal studies
por: Skuban, Aleksandar, et al.
Publicado: (2016)

PS155. Long-term safety of adjunctive brexpiprazole (OPC-34712) in MDD: results from two 52-week open-label studies
por: Nelson, Craig, et al.
Publicado: (2016)

Life Engagement Improvement Following Initiation of Brexpiprazole Treatment in Patients with MDD: A Naturalistic, Retrospective Real-World Study
por: Wee, Soon Nan, et al.
Publicado: (2023)

Experience with the Sheehan knee replacement.
por: McCoy, G. F., et al.
Publicado: (1983)

Sheehan's syndrome: Newer advances
por: Shivaprasad, C.
Publicado: (2011)

Sheehan's syndrome in two generations
por: Laway, Bashir Ahmad, et al.
Publicado: (2016)

Quality of life in Sheehan Syndrome
por: Mandal, Soumita, et al.
Publicado: (2022)

Fasting intolerance and recurrent hypoglycemia: Ponder for Sheehan's
por: Pahadiya, Hans Raj, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_bc5eefik61n7kl17mmckmm8h7k